Huberman & Attia Journal Club: Metformin for Longevity & The Dose-Response Placebo Effect

This inaugural Journal Club episode features Dr. Andrew Huberman and Dr. Peter Attia dissecting two significant scientific papers. Dr. Attia leads the discussion on Metformin, a long-standing drug for type 2 diabetes, exploring its potential role in longevity and geroprotection. He delves into its mechanism of action, primarily inhibiting mitochondrial complex I and reducing hepatic glucose output, and provides a detailed explanation of insulin resistance, its progression from hyperinsulinemia to elevated glucose, and the cellular mechanisms involved in glucose disposal. Attia also shares his personal history with Metformin and the broader excitement surrounding its anti-aging potential, contrasting it with drugs targeting specific diseases.

Dr. Huberman then presents a paper on the placebo effect, highlighting a novel finding: the placebo effect can exhibit a dose-response relationship, meaning its magnitude can scale with the perceived dose of a substance (in this case, nicotine). This challenges the traditional view of the placebo as an all-or-none phenomenon and underscores the profound capacity of belief to shape human physiology. The discussion emphasizes the critical role of scientists and clinicians in scrutinizing peer-reviewed research, asking whether studies truly support their claims, and distinguishing between robust findings and those requiring further investigation.

The episode also offers practical insights into metabolic health. Key factors contributing to insulin resistance, such as inactivity and sleep deprivation, are discussed, with exercise highlighted as a crucial preventative measure. The hosts touch upon tools like continuous glucose monitors (CGMs) for personalized health optimization and mention berberine as a natural compound with properties similar to metformin. The overarching goal is to equip listeners with the skills to critically evaluate scientific information and apply evidence-based tools for improving healthspan and longevity.

Beyond the specific papers, the episode serves as a masterclass in scientific literacy, demonstrating how experts parse complex data, debate findings, and extract actionable knowledge. It underscores the importance of understanding underlying biological mechanisms, the nuances of drug action, and the powerful, often underestimated, influence of the mind on the body. The discussion ultimately aims to empower the public with zero-cost, science-based information to make informed decisions about their health and well-being.

today you will be sitting in on the first huberman Atia Journal club... we will discuss two papers

Peter is going to discuss a paper on Metformin which is a drug that many people are interested in for its potential role in longevity I want to highlight potential there

the paper that we discussed today is that it shows that the placebo effect can actually follow a dose response so it's not just all or none

what scientists and clinicians do is they take a look at the existing peer-reviewed research and they look at that peer-reviewed research with a fresh eye asking does this paper really show know what it claims to show or not

metformin is a drug that has been used for many years... as a first line agent for patients with type 2 diabetes

the most efficient way that we make ATP is through oxidative phosphorylation

the difference between being metabolically healthy and having you know profound type 2 diabetes is one teaspoon of glucose in your bloodstream

exercising is one of the most important things you're going to do to ward off insulin resistance

sleep deprivation has a profound impact on insulin resistance

normal glycemia with hyperinsulinemia especially postprandial meaning after you eat hyperinsulinemia is the thing that tells you hey you're five ten years away from this being a real problem